Загрузка...
EPID-02. SURVIVAL BENEFIT OF GLIOBLASTOMA PATIENTS AFTER FDA APPROVAL OF BEVACIZUMAB, A POPULATION-BASED STUDY USING SEER, TCR, AND NCDB DATABASES
The nationwide studies on survival change in GBM patients treated with bevacizumab (BEV) after Food and Drug Administration (FDA) approval in May 2009 were limited. We investigated the impacts of BEV on survival in general GBM patient population by conducting a retrospective study based on the Surve...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5693197/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.280 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|